PENTAM
Pronunciation: pen-TAM-i-deen

What it isMacromolecular-biosynthesis inhibitor used IV for Pneumocystis treatment or inhaled for prophylaxis when preferred drugs fail.
Why this oneInhalation offers non-sulfonamide prophylaxis with less systemic exposure, while IV treatment reaches established disease.
What limits itParenteral use can cause fatal hypotension, dysglycemia, pancreatitis, renal injury, and arrhythmia; inhaled drug misses extrapulmonary sites.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Treatment of Pneumocystis pneumonia (P. carinii) | Adults | 4 mg/kg IV or deep IM QD | 4 mg/kg QD × 14–21 days | 4 mg/kg QD |
| Treatment of Pneumocystis pneumonia (P. carinii) | Peds >4 months | 4 mg/kg IV or deep IM QD | 4 mg/kg QD × 14–21 days | 4 mg/kg QD |
Renal Undefined
Hepatic Undefined
Use only when Pneumocystis has been demonstrated. Therapy >21 days has been used but may increase toxicity.
Available strengths
| Strength | #/mo | generic $/unit | CostPlus | |
|---|---|---|---|---|
| 300 mg | inj | per unit | not offered |
Generic entry1992
⚠ BOXED WARNING
Legacy pregnancy categoryUnknown / historical label unavailable
Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.